KYMR · ISSUER CIK 1815442
Kymera Therapeutics, Inc.
Between Aug 1, 2026 and Oct 29, 2026, 2 Kymera Therapeutics, Inc. insiders reported $0.00 of open-market purchases and $4.2M of sales on SEC Form 4.
↗2 insiders filed
Original Form 4 filings from Aug 1, 2026 to Oct 29, 2026. 1 of 2 sales were reported under a 10b5-1 plan.
$0.00Insider buying
$4.2MInsider selling
−$4.2MNet open-market
Oct 1, 2026Latest filing
| Ticker | Insider | Type | Owned | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Oct 1, 202617:20 | Oct 1, 2026 | KYMR | Chief Executive Officer, Director | S · Sell10b5-1 | $113.80 | −30,000 | 666,568 | -4% | −$3.4M | ||
| Oct 1, 202617:20 | Oct 1, 2026 | KYMR | Chief Executive Officer, Director | M · Exercise10b5-1 | $2.08 | +30,000 | 696,568 | +5% | $62K | ||
| Sep 4, 202618:00 | Sep 4, 2026 | KYMR | Chief Legal Officer | S · Sell | $116.83 | −6,371 | 50,254 | -11% | −$744K |